Latest Breaking News On - Nuvation bio inc - Page 1 : comparemela.com

Weekly Analysts' Ratings Updates for Nuvation Bio (NUVB)

Nuvation Bio (NYSE: NUVB) recently received a number of ratings updates from brokerages and research firms: 6/3/2024 – Nuvation Bio had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock. 5/24/2024 – Nuvation Bio had its “outperform” rating reaffirmed by analysts at Wedbush. They now […]

Canada
Nuvation-bio
Beacon-pointe-advisors
Pinnacle-wealth-planning-services-inc
Nuvation-bio-inc
News-ratings-for-nuvation-bio-inc-daily
Royal-bank
Susquehanna-fundamental-investments
Exchange-traded-concepts
Get-free-report
Pointe-advisors
Fundamental-investments

Nuvation Bio (NYSE:NUVB) Shares Down 7.7%

Nuvation Bio Inc. (NYSE:NUVB – Get Free Report)’s share price fell 7.7% on Monday . The company traded as low as $2.85 and last traded at $2.86. 677,357 shares were traded during mid-day trading, a decline of 44% from the average session volume of 1,220,003 shares. The stock had previously closed at $3.10. Analyst Upgrades […]

Canada
Nuvation-bio
Nuvation-bio-inc
Jefferies-financial-group
Beacon-pointe-advisors
Pinnacle-wealth-planning-services-inc
Exchange-traded-concepts
Royal-bank
Susquehanna-fundamental-investments
Get-free-report
Pointe-advisors
Fundamental-investments

Nuvation Bio (NYSE:NUVB) Shares Down 7.7%

Nuvation Bio Inc. (NYSE:NUVB – Get Free Report)’s share price fell 7.7% on Monday . The company traded as low as $2.85 and last traded at $2.86. 677,357 shares were traded during mid-day trading, a decline of 44% from the average session volume of 1,220,003 shares. The stock had previously closed at $3.10. Analyst Upgrades […]

Canada
Nuvation-bio
Exchange-traded-concepts
Royal-bank
Pinnacle-wealth-planning-services-inc
Susquehanna-fundamental-investments
Nuvation-bio-inc
Beacon-pointe-advisors
Jefferies-financial-group
Get-free-report
Pointe-advisors
Fundamental-investments

Nuvation Bio Announces Data from Pivotal Phase 2 TRUST-I Study of its Investigational ROS1 Inhibitor, Taletrectinib, are Published in the Journal of Clinical Oncology and Reported at 2024 ASCO Annual Meeting

Nuvation Bio Announces Data from Pivotal Phase 2 TRUST-I Study of its Investigational ROS1 Inhibitor, Taletrectinib, are Published in the Journal of Clinical Oncology and Reported at 2024 ASCO Annual Meeting
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Macau
Tongji
Sichuan
China
Chicago
Illinois
United-states
San-francisco
California
Hong-kong
New-york
Taiwan

Nuvation Bio's (NUVB) "Outperform" Rating Reiterated at Wedbush

Wedbush restated their outperform rating on shares of Nuvation Bio (NYSE:NUVB – Free Report) in a report released on Friday, Benzinga reports. The firm currently has a $5.00 price objective on the stock. Several other equities analysts also recently weighed in on NUVB. HC Wainwright reiterated a buy rating and issued a $8.00 price objective […]

Canada
Nuvation-bio
Exchange-traded-concepts
Susquehanna-fundamental-investments
Nuvation-bio-inc
Nuvation-bio-company-profile
Jefferies-financial-group
Beacon-pointe-advisors
Pinnacle-wealth-planning-services-inc
Royal-bank
Free-report
Financial-group